Here’s the detailed information for the Del(20q) (MDS) test, formatted professionally for use in brochures, lab catalogs, or doctor reference guides:

---

Test Name:

Del(20q) – Myelodysplastic Syndromes (MDS)

---

Clinical Significance:

The Deletion of the long arm of chromosome 20 [del(20q)] is a common cytogenetic abnormality observed in:

• Myelodysplastic Syndromes (MDS)

• Occasionally in Myeloproliferative Neoplasms (MPNs)

In MDS, del(20q) is generally considered to be associated with a favorable prognosis, especially when it occurs as an isolated abnormality (no other chromosomal changes).

---

Sample Requirements:

• Sample Type: Bone Marrow / Peripheral Blood

• Collection Tube: Sodium Heparin Vacutainer

• Volume: 2 mL

• Transport Conditions: Room temperature; avoid freezing.

---

Methodology:

• Fluorescence In Situ Hybridization (FISH)
  Detects deletions in the long arm of chromosome 20 (typically at 20q12 region).

---

Turnaround Time:

7–10 working days

---

Indications for Testing:

• Suspected or confirmed MDS

• Cytogenetic work-up during diagnosis or follow-up

• Prognostic assessment

• Monitoring of disease status post-treatment

---

Interpretation:

• Positive Result: Detection of 20q deletion — often suggests a lower-risk MDS subtype when isolated.

• Negative Result: No deletion detected; other chromosomal or molecular abnormalities may still exist.